Back to top

Image: Bigstock

Why Is Euronet Worldwide (EEFT) Down 2.9% Since Last Earnings Report?

Read MoreHide Full Article

A month has gone by since the last earnings report for Euronet Worldwide (EEFT - Free Report) . Shares have lost about 2.9% in that time frame, outperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Euronet Worldwide due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

How Have Estimates Been Moving Since Then?

It turns out, estimates review have trended downward during the past month.

The consensus estimate has shifted -19.61% due to these changes.

VGM Scores

At this time, Euronet Worldwide has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Euronet Worldwide has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry Player

Euronet Worldwide belongs to the Zacks Financial - Miscellaneous Services industry. Another stock from the same industry, Royalty Pharma (RPRX - Free Report) , has gained 0.7% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.

Royalty Pharma reported revenues of $742 million in the last reported quarter, representing a year-over-year change of +0.8%. EPS of $1.15 for the same period compares with $1.15 a year ago.

For the current quarter, Royalty Pharma is expected to post earnings of $1.02 per share, indicating a change of +4.1% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.7% over the last 30 days.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Royalty Pharma. Also, the stock has a VGM Score of C.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Royalty Pharma PLC (RPRX) - free report >>

Euronet Worldwide, Inc. (EEFT) - free report >>

Published in